77. Growth hormone secreting pituitary adenoma Clinical trials / Disease details


Clinical trial : 1 Drug : 1 - (DrugBank : 1) / Drug target genes : 2 - Drug target pathways : 20

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1800017714
2019-01-012018-08-10The Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgeryThe Effect and safety Assessment of Metformin Therapy in Growth Hormone-secreting Pituitary Adenoma (GH-PA) Patients who inoperable or incomplete control after surgery Growth Hormone-secreting Pituitary Adenoma (GH-PA)Bromocentine Group:bromocentine mesylate tablet, starting dose is 0.625-1.25mg/d and the weekly increase of 1.25mg/d until 10-15mg/d.;Bromocentine and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of bromocentine mesylate tablet;Gamma Knife Radiosurgery Group:Gamma Knife Radiosurgery;Gamma Knife Radiosurgery and Metformin Group:metformin hydrochloride enteric solution 0.5g three times a day added on the basis of gamma knife radiosurgery;Department of Endocrinology, Second Affiliated Hospital of Army Medical UniversityNULLPending1870BothBromocentine Group:10;Bromocentine and Metformin Group:10;Gamma Knife Radiosurgery Group:10;Gamma Knife Radiosurgery and Metformin Group:10;China